Screening | Baseline/Treatment/Safety | Follow-up | |||||||
---|---|---|---|---|---|---|---|---|---|
-21 to -1 days | Hours | Days | |||||||
0 | 3 | 24 | 21 | 180 | 185 | 360 | |||
Diagnosis (stool and urine examination) | X | X | X | X | |||||
Gut morbidity (stool RDTs) | X | X | X | X | |||||
Informed consent | X | ||||||||
Demographics | X | ||||||||
Medical history | X | ||||||||
Clinical examination | X | X | X | ||||||
Pregnancy testing | X | X | X | ||||||
Hemoglobin measurement | X | X | X | ||||||
Plasmodium co-infection (in Côte d’Ivoire/ Lao PDR only) | X | X | X | ||||||
W. bancrofti co-infection (in Africa only) | X | X | X | ||||||
Venous blood examination (in Côte d’Ivoire/ Lao PDR only) | X | X | X | X | |||||
Physical functioning | X | X | X | ||||||
Randomization and treatment | X | ||||||||
Selective re-treatment | X | ||||||||
Capturing AEs | X | X | X | ||||||
Capturing SAEs | X | X | X | ||||||
Treatment satisfaction | X | X | X |